REGIONAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PRIMARY-ACTIVE TUBERCULOSIS IN THE REPUBLIC OF AZERBAIJAN

Authors:

Abstract:

In the Republic of Azerbaijan, zones with a high incidence of tuberculosis, pulmonary and extrapulmonary tuberculosis among patients initially registered in these zones over the past three years (2021–2023) were analyzed. It was found that the incidence rate was higher in the mountainous-foothill zone, which accounts for 43.0 % of the country's territory. Thus, the incidence rate in zone II was 28.3 in 2021, which is 15.5 % higher than zone I and 26.9 % higher than zone III. The lowest incidence rate in 2022 was in the plain zone (22.9), and the highest was in the foothill-plain zone (32.1). This indicator is still the lowest in the plain zone (24 in 2023) and the highest in the foothill-plain zone (29.9). The number of patients initially registered in the foothill-plain zone over the last three years (2021–2023) accounts for more than half of the total number of patients initially registered in the country (51.5 %).

Keywords:

primary patients pulmonary tuberculosis drug resistance active tuberculosis

References:

1. Asadov DA, Aripov T, Alaverdyan S, Sadikkhodjayeva D, Yuldashev G, Allakova N, et al. Role of ethnicity and residency in active tuberculosis in Karakalpakstan: study protocol of a matched case-control study. BMJ Open Respir Res. 2024 Oct 26;11(1):e002554. doi: 10.1136/bmjresp-2024-002554.
2. Asadov DA, Khamraev AK, Yuldashev GK. Ethnogeographical features of tuberculosis incidence in the Southern Aral Sea region. Tuberculosis and lung diseases. 2023; 101 (4): 6–12. doi: 10.58838/2075-1230-2023-101-4-6-12.
3. Berezniakov VI, Korzh AN, Pavlov SB, Yeroshenko GA, Shevchenko KV, Pyvovar NM. Cytokines as mediators of the immune system and their role in the pathogenesis of community-acquired pneumonia. World of medicine and biology. 2021; 3 (77): 33–37. DOI: DOI 10.26724/2079-8334-2021-3-77-33-37.
4. Comella-del-Barrioa P, De Souza-Galvãob ML, Prat-Aymericha C, Domínguez J. Impact of COVID-19 on Tuberculosis Control. 2021; 57:S2. doi: 10.1016/j.arbres.2020.11.016.
5. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, et al; SATVI Clinical Immunology Team. Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Front Microbiol. 2019 Jun 26;10:1441. doi: 10.3389/fmicb.2019.01441.
6. Guseynalieva VN. Improving anti-tuberculosis measures in primary health care in the city and village and its impact on clinical and epidemiological indicators. Georgian Medical News. 2021;10: 81-86. PMID: 34749328.
7. Moore JE, Millar BC. Incidence of tuberculosis in Europe 2001-2021 and relationship to gross domestic product (GDP)-the continued need for levelling-up between European nations. Clin Microbiol Infect. 2024 Apr;30(4):561-563. doi: 10.1016/j.cmi.2024.01.011.
8. Tuberculosis surveillance and monitoring report in Europe 2020: 2018 data. ECDC, 2020. 190. doi: 10.2900/673523; TQ-AO-20-001-EN-N.
9. United Nations. The 17 goals: Sustainable development. 2023. Available at: https://sdgs.un.org/goals.
10. Vasiliu A, Köhler N, Altpeter E, Ægisdóttir TR, Amerali M, de Oñate WA, et al. Tuberculosis incidence in foreign-born people residing in European countries in 2020. Euro Surveill. 2023 Oct;28(42):2300051. doi: 10.2807/1560-7917.ES.2023.28.42.2300051.
11. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. ISBN: 978-92-4-155052-9.
12. WHO. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. ISBN 978-92-4-008385-1.

Publication:

«World of Medicine and Biology» Vol. 21 No. 94 (2025) , с. 12-16
УДК 616‑002.5:616‑036.22

DOI:

https://doi.org/10.26724/2079-8334-2025-4-94-12-16